CellaVision establishes subsidiary in Japan
"By establishing our own subsidiary in Japan we can effectively meet the demands on our products in the region. We look forward to be active on this potentially substantial market", says Yvonne Mårtensson.
The new subsidiary, CellaVision Japan K.K, will primarily prepare for sales by arranging for the licenses required for sales and support of Medtech products in Japan. The process is expected to come to completion during the third quarter this year. A small-sized sales organization will be set up during the year, with intentions of being operative when all licenses have been obtained.
Koichi Matsumoto most recently worked for Beckman Coulter in Japan. As Representative Director, Matsumoto will be responsible for sales of CellaVision's products to hematology laboratories in Japan. Matsumoto has several years of experience in sales of laboratory equipment to hospitals and private laboratories.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +4646-286 44 00. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden and has subsidiaries in Jupiter, FL, USA, and Toronto, ON, Canada. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.